Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of topical OPA-15406 ointment in mild to moderate atopic dermatitis
2013-003899-12Phase 2Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Aug 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of difamilast in atopic dermatitis (AD) (3 arms), sponsored by Otsuka Pharmaceutical Development & Commercialization. Primary endpoint: Safety, tolerability, and efficacy of topical OPA-15406 ointment. Started Aug 2014; status: completed.
02
Drugs
difamilast
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2013-003899-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003899-12.